% Expired Patents = 100.0

CIPO Patents = 1

EPO Patents = 1

Forward Citations = 11

Loading Chart...

1 inventor (with patents filed for the assignee):

Anton H Clemens (6 out of 20 patents)

6 patents: Sort by Forward Citations

1. 9987268 - Method of restoring the incretin effect (2018-06-05),

2. 8829018 - Method of restoring the incretin effect (2014-09-09),

3. 8785469 - Method of treating atherogenic dyslipidemia (2014-07-22),

4. 8445508 - Method of restoring the incretin effect (2013-05-21),

5. 8399474 - Method of restoring the incretin effect (2013-03-19),

6. 7893080 - Method of restoring the incretin effect (2011-02-22),

Company Overview

Neurendo Pharma, LLC is a pharmaceutical company specializing in the development and commercialization of innovative therapies for neurological disorders. With a focus on creating novel treatments for conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis, Neurendo Pharma is dedicated to improving the lives of patients worldwide.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

6 Patents

#95 in Madison, WI

#969 in Wisconsin

#44,949 in US

Madison, WI, United States of America

Neurendo Pharma, LLC

Forward Citations = 11

1 inventor:

Anton H Clemens (6 out of 20 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Neurendo Pharma, LLC. Retrieved from https://idiyas.com/company/neurendo-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]